The Practice of Medicinal Chemistry - Rilegato

Rilegato

ISBN 10: 0124172059 ISBN 13: 9780124172050

Casa editrice: Academic Press, 2015

Riassunto

The Practice of Medicinal Chemistry, Fourth Edition provides a practical and comprehensive overview of the daily issues facing pharmaceutical researchers and chemists. In addition to its thorough  treatment of basic medicinal chemistry principles, this updated edition has been revised to provide new and expanded coverage of the latest technologies and approaches in drug discovery.

With topics like high content screening, scoring, docking, binding free energy calculations, polypharmacology, QSAR, chemical collections and databases, and much more, this book is the go-to reference for all academic and pharmaceutical researchers who need a complete understanding of medicinal chemistry and its application to drug discovery and development.

• Includes updated and expanded material on systems biology, chemogenomics, computer-aided drug design, and other important recent advances in the field
• Incorporates extensive color figures, case studies, and practical examples to help users gain a further understanding of key concepts
• Provides high-quality content in a comprehensive manner, including contributions from international chapter authors to illustrate the global nature of medicinal chemistry and drug development research
• An image bank is available for instructors at www.textbooks.elsevier.com

Su questo libro

Recensione:

"...So that you are a young student of a faculty in the field of pharmacology looking for a formative text, a young researcher at the beginning of his or her experiential work or an expert in the "drug discovery" industry that only wants to deepen theme specifications, most likely in this book you will find what you need." (Google translation) --La Chimica e l’Industria

"...provides a diverse, multi-authored yet comprehensive update on the current state of the art in the science of medicinal chemistry...highly recommended for graduate students in the medicinal chemistry and drug discovery sciences." --Drug Development Research

Praise for the Third Edition: "The third edition of this book, useful to seasoned medicinal chemists as well as to chemists entering the academic or industrial laboratories, provides a hands-on overview of the drug discovery process. This edition differs from the previous two editions by having been updated to reflect developments in the past 5 years, and it includes 11 new chapters. I found this book to be unique, well organized, and overall a useful addition to the medicinal chemistry literature. Having favorably reviewed the first edition, I still highly recommend this third edition to all chemists who are involved in the drug discovery process." --John L. Neumeyer, Harvard Medical School, Journal of Medicinal Chemistry

"...a diverse, multi-authored yet comprehensive update on the current state of the art in the science of medicinal chemistry...highly recommended for graduate students in the medicinal chemistry and drug discovery sciences."--Drug Development Research

L'autore:

Camille-Georges Wermuth PhD, Prof. and Founder of Prestwick Chemical, was Professor of Organic Chemistry and Medicinal Chemistry at the Faculty of Pharmacy, Louis Pasteur University, Strasbourg, France from 1969 to 2002. He became interested in Medicinal Chemistry during his two years of military service in the French Navy at the "Centre d’Etudes Physio-biologiques Appliquées à la Marine" in Toulon. During this time he worked under the supervision of Dr Henri Laborit, the scientist who invented artificial hibernation and discovered chlorpromazine.

Professor Wermuths’ main research themes focus on the chemistry and the pharmacology of pyridazine derivatives. The 3-aminopyridazine pharmacophore, in particular, allowed him to accede to an impressive variety of biological activities, including antidepressant and anticonvulsant molecules; inhibitors of enzymes such as mono-amine-oxidases, phosphodiesterases and acetylcholinesterase; ligands for neuro-receptors: GABA-A receptor antagonists, serotonine 5-HT3 receptor antagonists, dopaminergic and muscarinic agonists. More recently, in collaboration with the scientists of the Sanofi Company, he developed potent antagonists of the 41 amino-acid neuropeptide CRF (corticotrophin-releasing factor) which regulates the release of ACTH and thus the synthesis of corticoids in the adrenal glands. Professor Wermuth has also, in collaboration with Professor Jean-Charles Schwartz and Doctor Pierre Sokoloff (INSERM, Paris), developed selective ligands of the newly discovered dopamine D3 receptor. After a three-year exploratory phase, this research has led to nanomolar partial agonists which may prove useful in the treatment of the cocaine-withdrawal syndrome.

Dr. Wermuth is co-author or editor of several books, the author of over 250 scientific papers and holds nearly 60 patents. Professor Wermuth is also the recipient of the Charles Mentzer Prize of the Société Française de Chimie Thérapeutique, the Léon Velluz Prize of the French Academy of Science, the Prix de l'Ordre des Pharmaciens by the French Academy of Pharmacy and the Nauta Award of the European Federation for Medicinal Chemistry for Pharmacochemistry in 2010.

Su questa edizione

• Editore: Academic Press
• Data di pubblicazione: 2015
• ISBN 10: 0124172059
• ISBN 13: 9780124172050
• Rilegatura: Copertina rigida
• Numero edizione: 4
• Numero di pagine: 902
• Redattore: Wermuth Camille Georges, Aldous David, Raboisson Pierre, Rognan Didier